Dr. Aguilera is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5323 Harry Hines Boulevard
Dallas, TX 75390Phone+1 214-645-8525Fax+1 214-645-8526
Education & Training
Stanford Health Care-Sponsored Stanford UniversityResidency, Radiation Oncology, 2012 - 2016
University of California (San Diego) Medical CenterInternship, Internal Medicine, 2011 - 2012
University of California San Diego School of MedicineMD PhD, Biomedical Sciences, 2003 - 2011
University of California San Diego School of MedicineClass of 2011
Certifications & Licensure
CA State Medical License 2012 - Present
TX State Medical License 2016 - 2026
American Board of Radiology Radiation Oncology
Clinical Trials
- INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer Start of enrollment: 2020 Apr 24
Publications & Presentations
PubMed
- 3 citationsNRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiation Therapy.Nina N Sanford, Amol K Narang, Todd A Aguilera, Michael F Bassetti, Michael D Chuong
International Journal of Radiation Oncology, Biology, Physics. 2025-03-15 - Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation.Zachary S Morris, Sandra Demaria, Arta M Monjazeb, Silvia C Formenti, Ralph R Weichselbaum
The Lancet. Oncology. 2025-03-01 - Evolving Paradigms in the Treatment of Oligometastatic Pancreatic Ductal Adenocarcinoma.Enoch Chang, Alexander D Sherry, Jakob Liermann, Amir Abdollahi, Ching-Wei D Tzeng
Journal of Gastrointestinal Cancer. 2025-01-18
Journal Articles
- Macrophages Promote Circulating Tumor Cell-Mediated Local Recurrence Following Radiation Therapy in Immunosuppressed PatientsTodd Aguilera, MD, Clinical Cancer Research
Press Mentions
What Does the Rectal Cancer Trial’s 100% Remission Rate Mean for Young Patients?July 21st, 2022
UTSW Receives $34 Million CPRIT Award for Cancer Research and Faculty RecruitmentSeptember 19th, 2017- Physician-Scientist Receives National Cancer Moonshot AwardAugust 17th, 2023
Grant Support
- Early response to radiotherapy and immunotherapy in rectal cancer: an integrated molecular, cellular, and spatial approachUT SOUTHWESTERN MEDICAL CENTER2023–2028
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
